What is the Thyrocare Technologies PE ratio today?
Thyrocare Technologies' PE ratio is 56.9 at the 29 October 2026 close (₹515.50 a share): a market capitalisation of ₹8,205 crore divided by consolidated net profit attributable to shareholders of ₹144 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹163 crore) it is 50.3. These four quarters include net exceptional items of −₹51.1 crore (one-off charges reported separately), so the ratio on recurring profit would differ.
What is the Thyrocare Technologies PB ratio (price to book value)?
Thyrocare Technologies' price-to-book (PB) ratio is 14.83 at the 29 October 2026 close: a market capitalisation of ₹8,205 crore divided by shareholders' equity (book value) of ₹553 crore on 30 September 2026. That is a book value of ₹34.77 per share against a share price of ₹515.50.
What is the Thyrocare Technologies ROE and ROCE?
In FY26, Thyrocare Technologies' return on equity (ROE) was 28.8% and its return on capital employed (ROCE) was 33.7%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 17.1% and ROCE 24.0%.
What is the Thyrocare Technologies market cap?
Thyrocare Technologies' market capitalisation was ₹8,205 crore at the 29 October 2026 close: 15.92 crore shares at ₹515.50 each.
Is Thyrocare Technologies debt free?
Yes. Thyrocare Technologies had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹206 crore of cash, bank balances and current investments.
What is the Thyrocare Technologies dividend in 2026 and its record date?
In 2026, Thyrocare Technologies has declared one dividend: ₹7 with record date 23 June 2026.
What is the Thyrocare Technologies debt to equity ratio?
Thyrocare Technologies' debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹552 crore. A year earlier, on 30 September 2025, it was 0.00.
What is the Thyrocare Technologies net worth?
Thyrocare Technologies' net worth — shareholders' equity in its consolidated balance sheet — was ₹553 crore on 30 September 2026, up 3.6% from ₹534 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹8,205 crore at the 29 October 2026 close.
What is the Thyrocare Technologies book value per share?
Thyrocare Technologies' book value per share was ₹34.77 on 30 September 2026: shareholders' equity of ₹553 crore divided by the 15.92 crore shares in issue. The share price at the 29 October 2026 close was ₹515.50.
What is the Thyrocare Technologies EPS?
Thyrocare Technologies' basic earnings per share (EPS) were ₹10.27 in FY26.
What is the Thyrocare Technologies promoter holding?
Promoters held 51.02% of Thyrocare Technologies on 30 September 2026, down 9.90 percentage points from 60.92% the previous quarter and down 20.04 percentage points from 71.06% a year earlier, according to the shareholding pattern filed with NSE.
What is the Thyrocare Technologies free cash flow?
In FY26, Thyrocare Technologies generated ₹213 crore of cash from operations and spent ₹20.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹192 crore. In FY25 it was ₹146 crore.
What is the Thyrocare Technologies shareholding pattern?
On 30 September 2026, Thyrocare Technologies' shares were held by promoters 51.02%, foreign portfolio investors (FII/FPI) 9.37%, domestic institutions (DII) 25.92% (including mutual funds at 22.91%) and retail and other non-institutional investors 13.70%. Over the year, FII holding was up 4.52 percentage points from 4.85% and DII holding was up 12.45 percentage points from 13.47%.
What are the Thyrocare Technologies latest quarterly results?
Thyrocare Technologies' latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit attributable to shareholders ₹15.9 crore, down 66.9% from ₹48 crore in Q2 FY26; revenue from operations ₹271 crore, up 25.1% year on year.
How does the Thyrocare Technologies PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Thyrocare Technologies' PE ratio is 50.3, the lowest of the four: Dr. Lal Path Labs 63.5, Metropolis Healthcare 60.4 and Vijaya Diagnostic Centre 87.1, a peer average of 70.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the Thyrocare Technologies revenue and profit in FY26?
In FY26 (April 2025–March 2026), Thyrocare Technologies' consolidated net profit attributable to shareholders was ₹163 crore, up 78.2% from ₹91.5 crore in FY25, on revenue from operations of ₹829 crore (up 20.6%). Over three years, from FY23, net profit was up 152.8%.
When are the Thyrocare Technologies next results?
Thyrocare Technologies has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
Thyrocare Technologies vs Dr. Lal Path Labs: how do they compare?
In FY26, Thyrocare Technologies earned net profit attributable to shareholders of ₹163 crore on revenue of ₹829 crore, against ₹505 crore on ₹2,763 crore for Dr. Lal Path Labs. Thyrocare Technologies' operating margin was 24.5% (Dr. Lal Path Labs 22.5%) and its return on equity 28.8% (Dr. Lal Path Labs 21.6%). At the 29 October 2026 close, Thyrocare Technologies' market capitalisation was ₹8,205 crore against ₹32,040 crore for Dr. Lal Path Labs, and its PE ratio on FY26 profit 50.3 against 63.5.
How does Thyrocare Technologies compare with its peers?
On FY26 consolidated figures, against Dr. Lal Path Labs, Metropolis Healthcare and Vijaya Diagnostic Centre: Thyrocare Technologies' operating margin of 24.5% is the second highest of the four (Dr. Lal Path Labs 22.5%, Metropolis Healthcare 16.2%, Vijaya Diagnostic Centre 30.1%; peer average 22.9%); its return on equity of 28.8% is the highest of the four (Dr. Lal Path Labs 21.6%, Metropolis Healthcare 13.4%, Vijaya Diagnostic Centre 19.7%; peer average 18.2%); its revenue growth over three years of 16.3% a year is the second highest of the four (Dr. Lal Path Labs 11.1% a year, Metropolis Healthcare 12.8% a year, Vijaya Diagnostic Centre 21.0% a year; peer average 14.9% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
